AbbVie reported third-quarter 2026 revenue growth of 10.3% and sharply higher earnings, with strength in its immunology and neuroscience portfolios. The company also completed its acquisition of Apogee Therapeutics, raised its full-year adjusted earnings outlook and announced a 5.2% increase in its dividend for 2027.
Key details
- Revenue and earnings: Worldwide net revenue was $17.404 billion, up 10.3% from a year earlier, or 10.5% excluding the effect of currency movements. Diluted earnings per share were $2.37 on a GAAP basis and $3.82 on an adjusted basis; both were more than double the year-earlier figures.
- Acquisition-related costs: Third-quarter results included a $0.11-per-share unfavorable impact from acquired in-process research and development and milestone expenses. Those costs totaled $0.69 per share for the first nine months of 2026 and are included in the company’s full-year outlook.
- Immunology: Revenue from the portfolio rose 16.3% to $9.165 billion, or 16.6% at constant currency. Skyrizi generated $5.776 billion, Rinvoq $2.706 billion and Humira $683 million.
- Neuroscience: Revenue grew 19.4% to $3.389 billion, or 19.5% at constant currency. Vraylar brought in $1.068 billion, Botox Therapeutic $1.080 billion, and Ubrelvy and Qulipta together $847 million. Vyalev generated $286 million.
- Oncology: Revenue was $1.696 billion, up 0.8%, or 0.9% at constant currency. Venclexta contributed $803 million, Imbruvica $522 million and Elahere $224 million.
- Aesthetics: Revenue fell 1.4% to $1.176 billion, or 1.8% at constant currency. Botox Cosmetic generated $669 million and Juvederm $222 million.
- Apogee acquisition: AbbVie completed its purchase of Apogee Therapeutics, which it said strengthens its immunology research pipeline. The announcement provided no purchase price or other transaction terms.
- Full-year outlook: AbbVie raised its 2026 adjusted earnings-per-share guidance to $13.95–$13.99, from $13.76–$13.96. The revised range includes the $0.69-per-share year-to-date impact from acquired research and development and milestone expenses.
- Dividend: The company announced a 5.2% increase to its dividend for 2027, beginning with the payment due in February.
What changes for investors
The raised earnings outlook reflects AbbVie’s stronger full-year expectations, while the Apogee acquisition adds to its immunology pipeline. The portfolio results were mixed: immunology and neuroscience grew at double-digit rates, oncology was nearly flat, and aesthetics declined.